Aurobindo Pharma's office in Japan: Tokyo, Japan
Business Address: 9th Floor, Youth Building, cho-ku, 103-0002, 1-3-8 Nihonbashibakuro-cho, Tokyo, Japan
Phone: +81 3-3249-2261
Fax: +81 3 3249 0828
E-mail: ntaku@aurobindo.com
Web: https://www.aurobindo.com/
| Type | Public |
|---|---|
| Traded as | NSE: AUROPHARMA BSE: 524804 |
| Industry | Pharmaceuticals |
| Founded | 1986 |
| Founders | V. Ramprasad Reddy K. Nityananda Reddy |
| Headquarters | Hyderabad, Telangana, India |
| Products |
|
| Revenue |  ₹23,290 crore (US$2.9 billion) (2020) |
| Operating income | ₹4,063 crore (US$510 million) (2020) |
| Net income | ₹2,844 crore (US$360 million) (2020) |
| Total assets | ₹28,926 crore (US$3.6 billion) (2020) |
| Total equity | ₹16,751 crore (US$2.1 billion) (2020) |
| Number of employees | 23,000 (2020) |
| Website | www.aurobindo.com |
Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.